Niagen Bioscience Inc
$3.21
The Read: 8% move when stabilizing EPS halted net income declines and share repurchases supported the stock, while typical earnings reactions near 4% occurred when modest beats and sales growth lacked new clinical catalysts.
Price
Overlays
Panel
NAGE
Hover to view data
No Data
